PHARMACY

Diplomat to dispense Verzenio

BY David Salazar

FLINT, Mich. — Diplomat Pharmacy has begun filling prescriptions for patients prescribed the recently approved breast cancer treatment Verzenio (abemaciclib). The drug was approved to treat certain cases of advanced or metastatic breast cancer, either alone or in combination with Faslodex.

"This therapy represents yet another step forward in the way the healthcare community approaches treating advanced stages of this disease,” Diplomat president Joel Saban said. “We are proud to support patients dealing with breast cancer by dispensing VERZENIO.”

The American Cancer Society projects that more than 250,000 breast cancer diagnoses will be made in 2017.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Bartell taps LexisNexis Risk Solutions, eRx Network for prescriber validation

BY David Salazar

SEATTLE — Bartell Drugs has become the first user of the strategic alliance between LexisNexis Risk Solutions and eRx Network for its prescriber validation. The pharmacy chain will leverage LexisNexis VerifyRx to perform real-time prescription compliance checks within their existing workflows.

"We were ready to take the next step in prescriber compliance and needed a turnkey solution that would not take resources away from our focus on patients," Bartell Drugs SVP pharmacy Peter Koo said. "The VerifyRx solution enables Bartell to take advantage of timely, accurate and comprehensive prescriber data via the LexisNexis Provider Data MasterFile, using eRx Network's connectivity to implement a solution directly within our pharmacy workflow."

VerifyRx lets pharmacies use the real-time connectivity of eRx Network and LexisNexis’ provider validation service on more than 8.5 million providers. It doesn’t require maintenance or IT integration efforts from the pharmacy chain, the companies said.

“We are pleased to be partnering with Bartell to deliver the vast capabilities of VerifyRx and the value provided by the seamless integration with the eRx Network,” LexisNexis Risk Solutions VP sales, pharmacy, Craig Ford said. “Verifying prescriber data in the workflow process is critical to pharmacies. Our strategic alliance has enabled us to respond to the needs of Bartell and other chains to deliver a leading, compliance-driven solution while using their existing connectivity.”

Other features include such risk mitigation features as a custom user interface and reporting tools.

"The combination of eRx Network's reliable network and the comprehensive prescriber compliance solution of LexisNexis Health Care will help make it easier and more efficient for Bartell to meet compliance requirements through its entire chain of stores," eRX Network SVP Richard Brook said. "We are confident that the implementation of our combined solutions will add value to Bartell's processes without causing any disruption to their workflows or increases to their operational costs or development efforts."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Dr. Reddy’s intros generic Renvela

BY David Salazar

HYDERABAD, India, and PRINCETON, N.J. — Dr. Reddy’s Laboratories recently launched its generic of Renvela (sevelamer carbonate) tablets. The drug is indicated to control serum phosphorus in adults and children ages 6 years and older with chronic kidney disease who are on dialysis.

“We are very pleased to bring Sevelamer Carbonate Tablets to market at this time,” Dr. Reddy’s EVP and head of North American generics Alok Sonig said. “This launch represents Dr. Reddy’s expertise and commitment to provide affordable alternatives for complex, limited-competition products to market.” This is the Company’s eighth overall and fourth limited-competition launch this fiscal year.

The Dr. Reddy’s generic is available in 800-mg dosage strength in 270-count bottles. For the 12 months ended July 2017, the drug had U.S. sales of roughly $1.88 billion, according to QuintilesIMS data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?